Search

Displaying results 4591 - 4600 of 8172 in total
  1. Drug

    Enviomycin

    go.drugbank.com/drugs/DB08993
    Experimental

    It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.

  2. Drug

    L523S

    go.drugbank.com/drugs/DB06498
    Investigational

    According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) … and when delivered following incorporation into an E1B-deleted adenovirus (Ad/L523S)."

  3. Drug

    Etacrynic acid

    go.drugbank.com/drugs/DB00903
    ApprovedInvestigational

    A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary ...

  4. Drug

    GS-100

    go.drugbank.com/drugs/DB18337
    Investigational

    GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence

  5. Drug

    Ecraprost

    go.drugbank.com/drugs/DB16148
    Investigational

    Ecraprost is under investigation in clinical trial NCT00059657 (Efficacy/safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease).

  6. Drug

    Elacytarabine

    go.drugbank.com/drugs/DB05494
    Investigational

    Elacytarabine is a fatty acid derivative of [cytarabine], an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia.

  7. Drug

    Matrix-M

    go.drugbank.com/drugs/DB16369
    Investigational

    Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. This compound is administered alongside vaccines to enhance biological functions: creating robust and long-last...

  8. Drug

    Aprepitant

    go.drugbank.com/drugs/DB00673
    ApprovedInvestigational

    Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting … Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Inducers
  9. Drug

    Gestrinone

    go.drugbank.com/drugs/DB11619
    Approved

    However, from 1982 this drug attracted increased interest due to significant therapeutic effects in the treatment endometriosis.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Velufenacin

    go.drugbank.com/drugs/DB21473
    Investigational

    Velufenacin has a monoisotopic molecular weight of 362.12 Da. … Velufenacin is under investigation in clinical trial NCT05282069 (A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder).